marketcaparena
Search

    DERM

    Journey Medical Corp

    Company overview

    Market capitalization
    —
    Employees
    58
    Latest publication
    2026-09-29
    About Journey Medical Corp

    Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue18,510,000USD15,961,000USD16,079,000USD17,631,000USD15,009,000USD13,139,000USD13,620,000USD14,629,000USD
    Cost Of Revenue6,143,000USD7,344,000USD6,505,000USD5,755,000USD6,003,000USD5,855,000USD2,237,000USD5,285,000USD
    Gross Profit12,367,000USD8,617,000USD9,574,000USD11,876,000USD9,006,000USD7,284,000USD11,383,000USD9,344,000USD
    Research Development54,000USD0USD154,000USD287,000USD0USD39,000USD218,000USD842,000USD
    Selling General Administrative10,888,000USD10,109,000USD9,863,000USD12,054,000USD11,882,000USD10,569,000USD10,060,000USD11,396,000USD
    Total Operating Expenses11,911,000USD10,109,000USD10,017,000USD13,405,000USD11,882,000USD10,608,000USD9,149,000USD12,238,000USD
    Operating Income456,000USD-1,492,000USD-443,000USD-1,529,000USD-2,876,000USD-3,324,000USD2,234,000USD-2,894,000USD
    Total Other Income Expense Net-753,000USD-738,000USD-804,000USD-786,000USD-860,000USD-749,000USD-652,000USD504,000USD
    Interest Expense906,000USD892,000USD933,000USD937,000USD937,000USD891,000USD831,000USD758,000USD
    Income Before Tax-297,000USD-2,230,000USD-1,247,000USD-2,315,000USD-3,736,000USD-4,073,000USD1,582,000USD-2,390,000USD
    Income Tax Expense15,000USD———60,000USD—61,000USD—
    Net Income-312,000USD-2,230,000USD-1,247,000USD-2,315,000USD-3,796,000USD-4,073,000USD1,521,000USD-2,390,000USD
    Interest Income—157,000USD148,000USD154,000USD138,000USD149,000USD191,000USD188,000USD
    Net Interest Income—-735,000USD-785,000USD-783,000USD-799,000USD-742,000USD-640,000USD-570,000USD
    Tax Provision—0USD0USD0USD60,000USD0USD61,000USD0USD
    Net Income From Continuing Ops—-2,230,000USD-1,247,000USD-2,315,000USD-3,796,000USD-4,073,000USD1,521,000USD-2,390,000USD
    Ebit—-1,492,000USD-443,000USD-1,378,000USD-2,876,000USD-3,324,000USD2,413,000USD-1,632,000USD
    Ebitda—-343,000USD645,000USD-314,000USD-1,790,000USD-2,238,000USD3,416,000USD-795,000USD
    Depreciation And Amortization—1,149,000USD1,088,000USD1,064,000USD1,086,000USD1,086,000USD1,003,000USD837,000USD
    Reconciled Depreciation—1,149,000USD1,088,000USD1,086,000USD1,086,000USD1,086,000USD1,003,000USD837,000USD
    Unclassified Operating Expenses———1,064,000USD——-1,129,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue61,858,000USD56,134,000USD79,181,000USD73,669,000USD63,134,000USD44,531,000USD34,921,000USD42,339,000USD
    Cost Of Revenue25,182,000USD20,879,000USD26,660,000USD30,775,000USD32,084,000USD14,594,000USD10,532,000USD1,176,000USD
    Gross Profit36,676,000USD35,255,000USD52,521,000USD42,894,000USD31,050,000USD29,937,000USD24,389,000USD41,163,000USD
    Research Development480,000USD9,857,000USD7,541,000USD10,943,000USD16,558,000USD0USD—80,547,000USD
    Selling General Administrative44,368,000USD40,204,000USD48,056,000USD59,468,000USD39,833,000USD22,086,000USD19,130,000USD172,581,000USD
    Total Operating Expenses44,848,000USD48,932,000USD54,594,000USD70,411,000USD65,931,000USD22,086,000USD19,130,000USD255,145,000USD
    Operating Income-8,172,000USD-13,677,000USD-2,073,000USD-27,517,000USD-34,881,000USD7,851,000USD5,259,000USD-213,982,000USD
    Interest Income589,000USD757,000USD259,000USD60,000USD2,000USD0USD——
    Interest Expense3,698,000USD2,700,000USD1,698,000USD2,019,000USD7,034,000USD698,000USD255,000USD15,639,000USD
    Net Interest Income-3,109,000USD-1,943,000USD-2,032,000USD-1,959,000USD-7,032,000USD-698,000USD-255,000USD—
    Income Before Tax-11,371,000USD-14,611,000USD-3,632,000USD-29,565,000USD-42,360,000USD7,153,000USD5,004,000USD-221,734,000USD
    Income Tax Expense60,000USD61,000USD221,000USD63,000USD1,634,000USD1,870,000USD1,379,000USD-194,000USD
    Tax Provision60,000USD61,000USD108,000USD63,000USD1,634,000USD1,870,000USD1,379,000USD—
    Net Income-11,431,000USD-14,672,000USD-3,853,000USD-29,628,000USD-43,994,000USD5,283,000USD3,625,000USD-221,540,000USD
    Net Income From Continuing Ops-11,431,000USD-14,672,000USD-12,352,000USD-29,628,000USD-43,994,000USD5,283,000USD3,625,000USD—
    Ebit-8,172,000USD-11,911,000USD-1,934,000USD-27,546,000USD-35,326,000USD7,851,000USD5,233,000USD-206,095,000USD
    Ebitda-3,826,000USD-8,396,000USD1,921,000USD-23,181,000USD-32,766,000USD9,276,000USD6,438,000USD-205,540,000USD
    Depreciation And Amortization4,346,000USD3,515,000USD3,855,000USD4,365,000USD2,560,000USD1,425,000USD1,205,000USD555,000USD
    Reconciled Depreciation4,346,000USD3,515,000USD4,265,000USD4,365,000USD2,560,000USD96,000USD90,000USD—
    Total Other Income Expense Net-3,199,000USD-934,000USD-1,559,000USD-2,048,000USD-7,479,000USD-698,000USD-255,000USD-7,752,000USD
    Unclassified Operating Expenses—-1,129,000USD-1,003,000USD—9,540,000USD———
    Net Income Applicable To Common Shares———-29,628,000USD-43,994,000USD5,283,000USD3,625,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets98,356,000USD91,534,000USD94,589,000USD85,191,000USD81,158,000USD84,962,000USD80,241,000USD64,044,000USD
    Cash And Equivalents25,643,000USD———————
    Total Current Assets72,781,000USD64,967,000USD66,873,000USD56,387,000USD51,268,000USD53,986,000USD48,179,000USD46,162,000USD
    Other Current Assets2,736,000USD3,464,000USD3,376,000USD1,638,000USD2,479,000USD2,395,000USD3,212,000USD1,242,000USD
    Total Liabilities66,242,000USD———————
    Total Current Liabilities45,770,000USD37,830,000USD37,442,000USD39,715,000USD40,481,000USD40,222,000USD35,175,000USD33,333,000USD
    Other Current Liabilities405,000USD———————
    Total Stockholder Equity32,114,000USD30,831,000USD31,852,000USD25,898,000USD19,246,000USD21,541,000USD20,069,000USD10,926,000USD
    Total Equity Including Noncontrolling Interest32,114,000USD———————
    Short Long Term Debt5,000,000USD2,500,000USD—5,625,000USD3,750,000USD1,875,000USD——
    Long Term Debt20,472,000USD22,873,000USD25,277,000USD19,534,000USD21,362,000USD23,105,000USD24,879,000USD19,785,000USD
    Net Receivables36,246,000USD24,992,000USD29,783,000USD17,983,000USD15,644,000USD18,025,000USD10,231,000USD10,671,000USD
    Inventory8,156,000USD9,292,000USD9,624,000USD11,818,000USD12,852,000USD12,496,000USD14,431,000USD11,788,000USD
    Property Plant Equipment Net65,000USD88,000USD111,000USD134,000USD156,000USD178,000USD199,000USD32,000USD
    Intangible Assets25,510,000USD26,479,000USD27,605,000USD28,670,000USD29,734,000USD30,798,000USD31,863,000USD17,844,000USD
    Accounts Payable8,049,000USD8,202,000USD9,306,000USD11,557,000USD12,754,000USD14,404,000USD16,050,000USD15,339,000USD
    Short Term Debt69,000USD2,594,000USD101,000USD5,723,000USD3,846,000USD1,968,000USD708,000USD34,000USD
    Retained Earnings-101,000,000USD-100,688,000USD-98,458,000USD-97,211,000USD-94,896,000USD-91,100,000USD-87,027,000USD-88,548,000USD
    Total Liab—60,703,000USD62,737,000USD59,293,000USD61,912,000USD63,421,000USD60,172,000USD53,118,000USD
    Other Current Liab—26,964,000USD27,965,000USD22,435,000USD23,810,000USD23,791,000USD18,357,000USD17,960,000USD
    Common Stock—2,000USD2,000USD3,000USD2,000USD2,000USD2,000USD2,000USD
    Capital Stock—3,000USD3,000USD3,000USD2,000USD2,000USD2,000USD2,000USD
    Cash—27,219,000USD24,090,000USD24,948,000USD20,293,000USD21,070,000USD20,305,000USD22,461,000USD
    Cash And Short Term Investments—27,219,000USD24,090,000USD24,948,000USD20,293,000USD21,070,000USD20,305,000USD22,461,000USD
    Net Debt—-1,752,000USD-23,971,000USD353,000USD4,984,000USD4,097,000USD5,400,000USD-2,642,000USD
    Short Long Term Debt Total—25,467,000USD119,000USD25,301,000USD25,277,000USD25,167,000USD25,705,000USD19,819,000USD
    Property Plant Equipment Gross—88,000USD111,000USD134,000USD156,000USD178,000USD199,000USD32,000USD
    Common Stock Shares Outstanding—27,305,028shares24,497,973shares24,959,114shares23,290,806shares22,611,040shares22,153,610shares20,537,794shares
    Non Current Assets Total—26,567,000USD27,716,000USD28,804,000USD29,890,000USD30,976,000USD32,062,000USD17,882,000USD
    Non Current Liabilities Total—22,873,000USD25,295,000USD19,578,000USD21,431,000USD23,199,000USD24,997,000USD19,785,000USD
    Net Working Capital—27,137,000USD29,431,000USD16,672,000USD10,787,000USD13,764,000USD13,004,000USD12,829,000USD
    Unclassified Current Liabilities—-2,430,000USD—-5,625,000USD-3,679,000USD-1,816,000USD——
    Unclassified Equity—131,514,000USD130,305,000USD123,103,000USD114,138,000USD112,637,000USD107,092,000USD99,470,000USD
    Non Currrent Assets Other———————6,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets94,589,000USD80,241,000USD76,849,000USD105,160,000USD97,284,000USD51,906,000USD33,859,000USD344,321,000USD
    Intangible Assets27,605,000USD31,863,000USD20,287,000USD27,197,000USD12,552,000USD15,029,000USD7,377,000USD952,000USD
    Other Current Assets3,376,000USD3,212,000USD3,588,000USD3,309,000USD2,438,000USD1,664,000USD655,000USD8,275,000USD
    Total Liab62,737,000USD60,172,000USD56,499,000USD88,178,000USD55,241,000USD41,614,000USD31,107,000USD353,360,000USD
    Total Stockholder Equity31,852,000USD20,069,000USD20,350,000USD16,982,000USD42,043,000USD10,292,000USD2,752,000USD-9,039,000USD
    Other Current Liab27,965,000USD18,357,000USD22,582,000USD26,783,000USD27,876,000USD21,498,000USD18,706,000USD19,415,000USD
    Common Stock2,000USD2,000USD2,000USD2,000USD2,000USD1,000USD1,000USD42,000USD
    Capital Stock3,000USD2,000USD2,000USD2,000USD2,000USD1,000USD1,000USD—
    Retained Earnings-98,458,000USD-87,027,000USD-72,355,000USD-68,502,000USD-38,874,000USD5,120,000USD-163,000USD-745,038,000USD
    Cash24,090,000USD20,305,000USD27,439,000USD32,003,000USD49,081,000USD8,246,000USD4,801,000USD104,976,000USD
    Cash And Short Term Investments24,090,000USD20,305,000USD27,439,000USD32,003,000USD49,081,000USD8,246,000USD4,801,000USD313,040,000USD
    Total Current Assets66,873,000USD48,179,000USD56,455,000USD77,679,000USD84,493,000USD35,242,000USD25,268,000USD335,409,000USD
    Total Current Liabilities37,442,000USD35,175,000USD41,868,000USD66,832,000USD51,606,000USD28,061,000USD20,897,000USD38,556,000USD
    Net Debt-23,971,000USD5,400,000USD-9,709,000USD-9,038,000USD-48,171,000USD1,678,000USD502,000USD208,813,000USD
    Short Term Debt101,000USD708,000USD3,099,000USD3,031,000USD910,000USD4,607,000USD83,000USD—
    Short Long Term Debt Total119,000USD25,705,000USD17,730,000USD22,965,000USD910,000USD9,924,000USD5,303,000USD313,789,000USD
    Long Term Debt25,277,000USD24,879,000USD14,622,000USD19,826,000USD—5,220,000USD5,220,000USD—
    Net Receivables29,783,000USD10,231,000USD15,222,000USD28,208,000USD23,112,000USD23,928,000USD18,955,000USD5,724,000USD
    Inventory9,624,000USD14,431,000USD10,206,000USD14,159,000USD9,862,000USD1,404,000USD857,000USD8,370,000USD
    Accounts Payable9,306,000USD16,050,000USD16,081,000USD36,983,000USD22,812,000USD1,956,000USD2,108,000USD15,948,000USD
    Property Plant Equipment Net111,000USD199,000USD101,000USD189,000USD89,000USD175,000USD89,000USD1,180,000USD
    Property Plant Equipment Gross111,000USD199,000USD101,000USD189,000USD89,000USD186,000USD95,000USD—
    Common Stock Shares Outstanding24,497,973shares20,431,400shares18,232,422shares17,531,274shares17,316,344shares16,659,645shares16,659,645shares42,003,000shares
    Non Current Assets Total27,716,000USD32,062,000USD20,394,000USD27,481,000USD12,791,000USD16,664,000USD8,591,000USD8,912,000USD
    Non Current Liabilities Total25,295,000USD24,997,000USD14,631,000USD21,346,000USD3,635,000USD13,553,000USD10,210,000USD314,804,000USD
    Net Working Capital29,431,000USD13,004,000USD14,587,000USD10,847,000USD32,887,000USD7,181,000USD4,371,000USD—
    Unclassified Equity130,305,000USD107,092,000USD92,701,000USD85,480,000USD80,913,000USD5,170,000USD2,913,000USD736,974,000USD
    Current Deferred Revenue—-588,000USD53,000USD4,991,000USD23,374,000USD21,615,000USD——
    Non Currrent Assets Other——6,000USD95,000USD150,000USD6,000USD6,000USD3,047,000USD
    Other Assets———95,000USD150,000USD1,460,000USD1,125,000USD—
    Short Long Term Debt———2,948,000USD812,000USD———
    Non Current Liabilities Other———1,412,000USD3,627,000USD8,137,000USD4,990,000USD—
    Net Tangible Assets———-10,215,000USD29,491,000USD-4,737,000USD-4,625,000USD—
    Unclassified Current Liabilities———-7,904,000USD-24,178,000USD-21,615,000USD—3,193,000USD
    Other Liab————8,000USD99,000USD——
    Accumulated Other Comprehensive Income————0USD—0USD-1,017,000USD
    Good Will———————771,000USD
    Short Term Investments———————208,064,000USD
    Unclassified Non Current Assets———————2,962,000USD
    Unclassified Non Current Liabilities———————314,804,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation2,095,000USD
    Stock Based Compensation2,426,000USD
    Change To Account Receivables-6,482,000USD
    Change To Inventory1,468,000USD
    Change To Liabilities3,462,000USD
    Change In Working Capital-5,246,000USD
    Operating Cash Flow1,175,000USD
    Financing Cash Flow378,000USD
    Change In Cash1,553,000USD
    End Cash Flow25,643,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-2,230,000USD-1,247,000USD-2,315,000USD-3,796,000USD-4,073,000USD1,521,000USD-2,390,000USD-3,361,000USD
    Depreciation1,149,000USD1,088,000USD1,086,000USD1,086,000USD1,086,000USD1,003,000USD837,000USD839,000USD
    Stock Based Compensation989,000USD1,775,000USD1,854,000USD1,336,000USD1,323,000USD1,378,000USD1,640,000USD1,674,000USD
    Other Non Cash Items1,115,000USD1,777,000USD2,053,000USD-317,000USD296,000USD-213,000USD-367,000USD210,000USD
    Change To Account Receivables4,761,000USD-11,759,000USD-2,415,000USD2,822,000USD-7,989,000USD747,000USD-877,000USD-812,000USD
    Change To Inventory332,000USD2,194,000USD1,034,000USD-356,000USD1,935,000USD-2,643,000USD-2,101,000USD893,000USD
    Change In Working Capital2,875,000USD-7,977,000USD-3,207,000USD749,000USD-1,464,000USD-1,464,000USD-877,000USD-4,538,000USD
    Total Cash From Operating Activities2,909,000USD-6,359,000USD-2,383,000USD-942,000USD-2,832,000USD2,225,000USD-1,157,000USD-5,176,000USD
    Capital Expenditures0USD0USD0USD0USD0USD0USD0USD0USD
    Free Cash Flow2,909,000USD-6,359,000USD-2,383,000USD-942,000USD-2,832,000USD2,225,000USD-1,157,000USD-5,176,000USD
    Net Borrowings0USD16,359,000USD0USD0USD-625,000USD12,302,000USD-675,000USD—
    Total Cash From Financing Activities220,000USD5,501,000USD7,038,000USD165,000USD3,597,000USD10,619,000USD-294,000USD5,031,000USD
    Issuance Of Capital Stock0USD—6,891,000USD0USD4,048,000USD—194,000USD0USD
    Change In Cash3,129,000USD-858,000USD4,655,000USD-777,000USD765,000USD-2,156,000USD-1,451,000USD-145,000USD
    Begin Period Cash Flow24,090,000USD24,948,000USD20,293,000USD21,070,000USD20,305,000USD22,461,000USD23,912,000USD24,057,000USD
    End Period Cash Flow27,219,000USD24,090,000USD24,948,000USD20,293,000USD21,070,000USD20,305,000USD22,461,000USD23,912,000USD
    Other Cashflows From Financing Activities220,000USD75,000USD-75,000USD—-451,000USD16,622,000USD187,000USD31,000USD
    Unclassified Operating Cash Flow—-1,775,000USD-1,854,000USD—————
    Unclassified Financing Cash Flow—-10,933,000USD———-18,305,000USD—5,000,000USD
    Investments—————-15,000,000USD0USD0USD
    Total Cashflows From Investing Activities—————-15,000,000USD——
    Other Cashflows From Investing Activities—————-15,000,000USD——
    Unclassified Investing Cash Flow—————15,000,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-11,431,000USD-14,672,000USD-3,853,000USD-29,628,000USD-43,994,000USD5,283,000USD3,625,000USD-221,540,000USD
    Depreciation4,724,000USD3,424,000USD3,855,000USD4,365,000USD2,560,000USD1,516,000USD1,264,000USD555,000USD
    Stock Based Compensation6,288,000USD6,098,000USD2,606,000USD4,425,000USD2,466,000USD153,000USD240,000USD29,843,000USD
    Other Non Cash Items-123,000USD-211,000USD4,287,000USD1,117,000USD20,512,000USD747,000USD355,000USD132,641,000USD
    Change To Account Receivables-19,341,000USD4,475,000USD12,551,000USD-5,380,000USD768,000USD-5,022,000USD-10,492,000USD-5,672,000USD
    Change To Inventory4,807,000USD-4,225,000USD3,953,000USD1,744,000USD-8,458,000USD-547,000USD-179,000USD-8,370,000USD
    Change In Working Capital-11,899,000USD-3,766,000USD-1,655,000USD6,187,000USD14,709,000USD-2,232,000USD3,465,000USD-154,403,000USD
    Total Cash From Operating Activities-12,441,000USD-9,127,000USD5,240,000USD-13,534,000USD-2,181,000USD5,132,000USD9,018,000USD-213,098,000USD
    Capital Expenditures0USD-15,000,000USD-5,000,000USD-20,000,000USD-10,000,000USD-1,200,000USD-2,400,000USD-616,000USD
    Free Cash Flow-12,441,000USD-9,127,000USD240,000USD-33,534,000USD-12,181,000USD3,932,000USD6,618,000USD-213,714,000USD
    Net Borrowings15,734,000USD16,627,000USD-4,454,000USD16,899,000USD5,052,000USD-500,000USD-3,551,000USD—
    Total Cash From Financing Activities16,226,000USD16,993,000USD-4,804,000USD16,456,000USD53,016,000USD-487,000USD-3,551,000USD35,381,000USD
    Change In Cash3,785,000USD-7,134,000USD-4,564,000USD-17,078,000USD40,835,000USD3,445,000USD3,067,000USD-190,945,000USD
    Begin Period Cash Flow20,305,000USD27,439,000USD32,003,000USD49,081,000USD8,246,000USD4,801,000USD1,734,000USD295,923,000USD
    End Period Cash Flow24,090,000USD20,305,000USD27,439,000USD32,003,000USD49,081,000USD8,246,000USD4,801,000USD104,978,000USD
    Other Cashflows From Financing Activities-75,000USD366,000USD-350,000USD-214,000USD16,971,000USD13,000USD449,000USD35,381,000USD
    Investments—-15,000,000USD-5,000,000USD-20,000,000USD-10,000,000USD-1,200,000USD-2,400,000USD—
    Total Cashflows From Investing Activities—-15,000,000USD-5,000,000USD-20,000,000USD-10,000,000USD-1,200,000USD-2,400,000USD-13,228,000USD
    Other Cashflows From Investing Activities—-15,000,000USD-5,000,000USD-20,000,000USD-10,000,000USD-1,200,000USD—-56,000,000USD
    Unclassified Investing Cash Flow—30,000,000USD10,000,000USD40,000,000USD20,000,000USD2,400,000USD2,400,000USD43,388,000USD
    Issuance Of Capital Stock——4,494,000USD32,536,000USD51,503,000USD0USD——
    Unclassified Financing Cash Flow——-4,494,000USD—34,093,000USD——-2,146,000USD
    Change To Liabilities———0USD21,713,000USD-152,000USD1,148,000USD—
    Dividends Paid———-371,000USD-1,550,000USD———
    Sale Purchase Of Stock———-371,000USD-1,550,000USD——2,146,000USD
    Unclassified Operating Cash Flow————1,566,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductAccutane3,314,000USD0001104659-26-060297
    Q1 2026Quarterly · 2026-03-31ProductEmrosi6,252,000USD0001104659-26-060297
    Q1 2026Quarterly · 2026-03-31ProductFoam Franchise Products Amzeeq Zilxi1,050,000USD0001104659-26-060297
    Q1 2026Quarterly · 2026-03-31ProductOther Legacy277,000USD0001104659-26-060297
    Q1 2026Quarterly · 2026-03-31ProductQbrexza5,028,000USD0001104659-26-060297
    FY 2025Yearly · 2025-12-31ProductAccutane12,882,000USD0001104659-26-034629
    FY 2025Yearly · 2025-12-31ProductEmrosi14,745,000USD0001104659-26-034629
    FY 2025Yearly · 2025-12-31ProductFoam Franchise Products Amzeeq Zilxi5,859,000USD0001104659-26-034629
    FY 2025Yearly · 2025-12-31ProductOther Legacy2,739,000USD0001104659-26-034629
    FY 2025Yearly · 2025-12-31ProductQbrexza25,014,000USD0001104659-26-034629
    Q3 2025Quarterly · 2025-09-30ProductAccutane2,769,000USD0001104659-25-110457
    Q3 2025Quarterly · 2025-09-30ProductEmrosi4,883,000USD0001104659-25-110457
    Q3 2025Quarterly · 2025-09-30ProductFoam Franchise Products Amzeeq Zilxi1,311,000USD0001104659-25-110457
    Q3 2025Quarterly · 2025-09-30ProductOther Legacy701,000USD0001104659-25-110457
    Q3 2025Quarterly · 2025-09-30ProductQbrexza7,361,000USD0001104659-25-110457
    Q2 2025Quarterly · 2025-06-30ProductAccutane3,395,000USD0001410578-25-001703
    Q2 2025Quarterly · 2025-06-30ProductAmzeeq879,000USD0001410578-25-001703
    Q2 2025Quarterly · 2025-06-30ProductEmrosi2,795,000USD0001410578-25-001703
    Q2 2025Quarterly · 2025-06-30ProductOther Legacy735,000USD0001410578-25-001703
    Q2 2025Quarterly · 2025-06-30ProductQbrexza6,949,000USD0001410578-25-001703
    Q2 2025Quarterly · 2025-06-30ProductZilxi256,000USD0001410578-25-001703
    Q1 2025Quarterly · 2025-03-31ProductAccutane3,655,000USD0001410578-25-001296
    Q1 2025Quarterly · 2025-03-31ProductAmzeeq1,100,000USD0001410578-25-001296
    Q1 2025Quarterly · 2025-03-31ProductEmrosi2,070,000USD0001410578-25-001296
    Q1 2025Quarterly · 2025-03-31ProductOther Legacy727,000USD0001410578-25-001296
    Q1 2025Quarterly · 2025-03-31ProductQbrexza5,161,000USD0001410578-25-001296
    Q1 2025Quarterly · 2025-03-31ProductZilxi426,000USD0001410578-25-001296
    Q4 2024Quarterly · 2024-12-31ProductAccutane3,873,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductAmzeeq1,507,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOther Legacy1,119,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductQbrexza5,678,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductZilxi443,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductAccutane19,407,000USD0001410578-25-000490
    FY 2024Yearly · 2024-12-31ProductAmzeeq5,009,000USD0001410578-25-000490
    FY 2024Yearly · 2024-12-31ProductOther Legacy3,961,000USD0001410578-25-000490
    FY 2024Yearly · 2024-12-31ProductQbrexza25,114,000USD0001410578-25-000490
    FY 2024Yearly · 2024-12-31ProductZilxi1,643,000USD0001410578-25-000490
    Q3 2024Quarterly · 2024-09-30ProductAccutane3,996,000USD0001410578-24-001877
    Q3 2024Quarterly · 2024-09-30ProductAmzeeq1,542,000USD0001410578-24-001877
    Q3 2024Quarterly · 2024-09-30ProductOther Legacy950,000USD0001410578-24-001877
    Q3 2024Quarterly · 2024-09-30ProductQbrexza7,583,000USD0001410578-24-001877
    Q3 2024Quarterly · 2024-09-30ProductZilxi558,000USD0001410578-24-001877
    Q2 2024Quarterly · 2024-06-30ProductAccutane5,719,000USD0001410578-25-001703
    Q2 2024Quarterly · 2024-06-30ProductAmzeeq1,205,000USD0001410578-25-001703
    Q2 2024Quarterly · 2024-06-30ProductOther Legacy726,000USD0001410578-25-001703
    Q2 2024Quarterly · 2024-06-30ProductQbrexza6,836,000USD0001410578-25-001703
    Q2 2024Quarterly · 2024-06-30ProductZilxi369,000USD0001410578-25-001703
    Q1 2024Quarterly · 2024-03-31ProductAccutane5,819,000USD0001410578-25-001296
    Q1 2024Quarterly · 2024-03-31ProductAmzeeq755,000USD0001410578-25-001296
    Q1 2024Quarterly · 2024-03-31ProductOther Legacy1,166,000USD0001410578-25-001296
    Q1 2024Quarterly · 2024-03-31ProductQbrexza5,017,000USD0001410578-25-001296
    Q1 2024Quarterly · 2024-03-31ProductZilxi273,000USD0001410578-25-001296
    FY 2023Yearly · 2023-12-31ProductAccutane20,168,000USD0001410578-25-000490
    FY 2023Yearly · 2023-12-31ProductAmzeeq6,201,000USD0001410578-25-000490
    FY 2023Yearly · 2023-12-31ProductOther Legacy5,921,000USD0001410578-25-000490
    FY 2023Yearly · 2023-12-31ProductQbrexza25,410,000USD0001410578-25-000490
    FY 2023Yearly · 2023-12-31ProductZilxi1,962,000USD0001410578-25-000490
    FY 2021Yearly · 2021-12-31ProductAccutane10,053,000USD0001410578-22-000558
    FY 2021Yearly · 2021-12-31ProductExelderm5,363,000USD0001410578-22-000558
    FY 2021Yearly · 2021-12-31ProductOther Branded Products37,000USD0001410578-22-000558
    FY 2021Yearly · 2021-12-31ProductQbrexa17,056,000USD0001410578-22-000558
    FY 2021Yearly · 2021-12-31ProductTargadox22,378,000USD0001410578-22-000558
    FY 2021Yearly · 2021-12-31ProductXimino8,247,000USD0001410578-22-000558
    FY 2020Yearly · 2020-12-31ProductExelderm4,453,000USD0001410578-22-000558
    FY 2020Yearly · 2020-12-31ProductOther Branded Products-148,000USD0001410578-22-000558
    FY 2020Yearly · 2020-12-31ProductTargadox30,708,000USD0001410578-22-000558
    FY 2020Yearly · 2020-12-31ProductXimino9,518,000USD0001410578-22-000558
    FY 2018Yearly · 2018-12-31ProductLicense And Service39,379,000USD0001564590-19-004452
    FY 2018Yearly · 2018-12-31ProductProduct2,960,000USD0001564590-19-004452

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.